Equities

Mangoceuticals Inc

MGRX:NAQ

Mangoceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.382
  • Today's Change0.00 / 0.00%
  • Shares traded146.26k
  • 1 Year change-74.19%
  • Beta--
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.

  • Revenue in USD (TTM)844.87k
  • Net income in USD-9.02m
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Interpace Biosciences Inc40.66m1.25m6.33m108.005.16--3.200.15580.28020.20229.27-3.342.9014.328.37376,481.508.95-38.19---69.7359.0249.443.08-41.010.43553.11----26.3112.93118.96--0.9184--
Biocorrx Inc52.35k-3.99m7.02m5.00------134.05-0.464-0.4640.0061-1.210.102--0.9969---778.76-291.68----44.6467.13-7,635.86-3,208.40---3.49-----58.31-25.0413.79------
Selectis Health Inc36.67m-9.06m7.67m574.00------0.2091-2.96-2.9611.99-1.310.8309--15.6863,884.65-20.46-3.03-30.08-3.58-----24.63-4.84---3.361.12---9.4058.97-64.93---47.72--
Syra Health Corp6.08m-3.60m8.93m78.00--2.66--1.47-0.5946-0.59461.050.52241.77--10.1977,937.56-105.01---154.43--23.75---59.21-----83.830.0279---1.83---38.72------
Mangoceuticals Inc844.87k-9.02m9.77m--------11.56-0.492-0.4920.0455-0.04060.3826-------408.41---596.95--61.75---1,067.52--0.0622------8,082.22---361.07------
Pacific Health Care Organization Inc5.72m834.22k10.05m30.0012.060.913411.531.760.06510.06510.44590.85950.4725--6.09190,503.306.907.297.427.8179.4282.7514.6013.28----0.00---2.00-3.7055.80-10.80-15.93--
Caremax Inc810.36m-644.67m11.14m1.45k--0.5461--0.0138-172.31-172.31216.425.360.9467--6.07558,871.80-75.32---114.67---0.1988---79.55-----1.840.9506--19.01---1,707.99------
Medical Care Technologies Inc.0.00-1.07m11.23m0.00---------553,570.10-553,570.100.00-389.230.00-------154.94-----------------1.46---------40.06------
Xcelerate Inc3.96m-296.19k12.11m1.00--8.70--3.06-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)94.26m-5.17m12.42m1.29k--1.843.460.1318-0.1178-0.11782.210.14131.2316.6085.1473,297.39-7.21-23.36-44.53-48.5847.1855.32-5.85-23.720.2333-3.700.8791--1.86-2.1650.91--3.70--
Univec Inc-100.00bn-100.00bn12.87m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Clearday Inc7.54m-21.54m13.35m225.00------1.77-0.9722-0.99380.3147-1.700.3432--201.6333,524.13-77.04-71.37---342.36-----224.52-205.25---0.9413-----3.0594.7325.38---28.32--
NewGenIvf Group Ltd0.00-690.85k13.90m----0.3273-----0.1999-0.19990.004.190.00-------1.50---1.54--------------0.0944-------237.99------
Psychemedics Corp.21.60m-4.46m13.93m116.00--2.22--0.6452-0.773-0.7733.741.081.49--5.44186,172.40-30.68-7.44-46.72-9.7038.5737.55-20.64-6.26---184.940.0353---12.45-12.33-283.21---33.32--
Data as of Jun 06 2024. Currency figures normalised to Mangoceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

1.39%Per cent of shares held by top holders
HolderShares% Held
Citadel Securities LLCas of 31 Mar 2024114.40k0.48%
Mercer Global Advisors, Inc.as of 31 Mar 2024100.00k0.42%
McCollum Christoferson Group LLCas of 31 Mar 202442.70k0.18%
XTX Markets LLCas of 31 Mar 202424.35k0.10%
Desjardins Securities, Inc.as of 31 Mar 202422.00k0.09%
UBS Securities LLCas of 31 Mar 202414.45k0.06%
Morgan Stanley & Co. LLCas of 31 Mar 202410.36k0.04%
BFSG LLCas of 31 Mar 2024200.000.00%
Renaissance Technologies LLCas of 31 Mar 20240.000.00%
Vanguard Capital Wealth Advisors LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.